摘要:
Conjugates of specific PBD dimers with an antibody that that binds to CD19, the antibody comprising a VH domain having the sequence according to any one of SEQ ID NOs. 1, 2, 3, 4, 5 or 6, optionally further comprising a VL domain having the sequence according to any one of SEQ ID NOs. 7, 8, 9, 10, 11 or 12.
摘要:
Site-specific anti-body-drug conjugates are described, in particular conjugates comprising an antibody, which binds HER2 and comprises an amino acid substitution of an interchain cysteine residue by an amino acid that is not cysteine, and pyrrolobenzodiazepines (PBDs) having a labile protecting group in the form of a linker. The site of conjugation, along with modification of the antibody moiety, allows for improved safety and efficacy of the ADC.
摘要:
The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.